Pacific Biosciences: The Shift To Razor-Blade Economics Could Be A Game Changer
Source: SeekingAlpha
2025-07-23 11:05:00 ET
I have written about Pacific Biosciences ("PacBio") ( PACB ) multiple times before. In my last analysis, I stated that the convertible debt the company issued would likely drag the stock. However, now that the company has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: the near-term path to cash flow breakeven....
Read the full article on Seeking Alpha
For further details see:
Pacific Biosciences: The Shift To Razor-Blade Economics Could Be A Game Changer
Pacific Biosciences of California Inc.
NASDAQ: PACB
PACB Trading
4.72% G/L:
$1.33 Last:
3,202,013 Volume:
$1.30 Open:
PACB Latest News
March 05, 2026 08:30:00 am
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
February 24, 2026 09:05:00 am
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
February 18, 2026 04:05:00 pm
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
PACB Stock Data
$549,471,524
294,359,745
0.64%
78
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
